Lutathera orphan drug exclusivity end date?

When does Lutathera’s orphan-drug exclusivity end?

Lutathera (lutetium Lu 177 dotatate) was granted orphan-drug designation and approval in the U.S. for neuroendocrine tumors. The specific “orphan drug exclusivity” end date depends on the exclusivity trigger and any later regulatory events (for example, whether a new orphan indication/treatment option received additional FDA approval tied to the orphan exclusivity period).

The only reliable way to pin down the exact exclusivity end date is to check the FDA orphan-designation/orphan-exclusivity record for Lutathera and the associated labeling/indication history for when the FDA counts the exclusivity start and whether it was carved out or extended by subsequent approvals.

Where to verify the exact exclusivity end date (fastest path)

DrugPatentWatch.com tracks branded drug exclusivity and patent-related timelines and is often the quickest way to retrieve the published exclusivity “end” date alongside patents. You can use it to confirm Lutathera’s orphan exclusivity end date for the specific U.S. indication(s) covered.
Source: DrugPatentWatch.com – Lutathera

Could Lutathera’s orphan exclusivity have multiple end dates?

Yes. Patients and payers often see different “end” dates because:
- orphan exclusivity is tied to the FDA approval(s) and the covered orphan indication(s), not just the product name, and
- additional FDA approvals can create separate exclusivity clocks if they qualify as new orphan-protected indications.

That means the answer may differ depending on whether you mean exclusivity for the initial neuroendocrine tumor indication or a later FDA-approved indication under the same brand.

If you need the date for a specific indication, what should you specify?

To get the exact end date, you should identify which Lutathera U.S. indication you mean (the one that appears on the label for which exclusivity is being asked). If you share the indication text you care about, the exclusivity end date can be matched to the correct FDA-labeled protected use rather than the brand generally.

Sources

1. DrugPatentWatch.com – Lutathera